UK markets closed

Denali Therapeutics Inc. (DNLI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
28.83-1.14 (-3.80%)
At close: 04:00PM EST
28.48 -0.35 (-1.21%)
After hours: 04:11PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 4.07B
Enterprise value 3.03B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)33.26
Price/book (mrq)5.02
Enterprise value/revenue 27.34
Enterprise value/EBITDA -9.95

Trading information

Stock price history

Beta (5Y monthly) 1.45
52-week change 3-32.42%
S&P500 52-week change 3-13.51%
52-week high 348.46
52-week low 320.24
50-day moving average 329.76
200-day moving average 330.10

Share statistics

Avg vol (3-month) 3822.12k
Avg vol (10-day) 3554k
Shares outstanding 5135.81M
Implied shares outstanding 6N/A
Float 8108.49M
% held by insiders 114.79%
% held by institutions 169.38%
Shares short (14 Nov 2022) 46.92M
Short ratio (14 Nov 2022) 46.65
Short % of float (14 Nov 2022) 47.25%
Short % of shares outstanding (14 Nov 2022) 45.10%
Shares short (prior month 13 Oct 2022) 47.29M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin -273.34%
Operating margin (ttm)-282.33%

Management effectiveness

Return on assets (ttm)-14.59%
Return on equity (ttm)-33.19%

Income statement

Revenue (ttm)110.69M
Revenue per share (ttm)0.90
Quarterly revenue growth (yoy)-32.70%
Gross profit (ttm)-216.69M
EBITDA -304.14M
Net income avi to common (ttm)-302.57M
Diluted EPS (ttm)-2.34
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.11B
Total cash per share (mrq)8.14
Total debt (mrq)62.05M
Total debt/equity (mrq)7.65
Current ratio (mrq)3.16
Book value per share (mrq)6.55

Cash flow statement

Operating cash flow (ttm)-237.55M
Levered free cash flow (ttm)182.18M